KR20250004896A - Cd47 및 egfr의 이중 표적화를 이용한 암의 치료 - Google Patents

Cd47 및 egfr의 이중 표적화를 이용한 암의 치료 Download PDF

Info

Publication number
KR20250004896A
KR20250004896A KR1020247039741A KR20247039741A KR20250004896A KR 20250004896 A KR20250004896 A KR 20250004896A KR 1020247039741 A KR1020247039741 A KR 1020247039741A KR 20247039741 A KR20247039741 A KR 20247039741A KR 20250004896 A KR20250004896 A KR 20250004896A
Authority
KR
South Korea
Prior art keywords
egfr
cancer cells
antibody
cells
expressing cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247039741A
Other languages
English (en)
Korean (ko)
Inventor
어빙 엘. 와이즈먼
켈리 마리 맥켄나
스테판 윌링햄
도리스 포 이 호
피에로 디. 달러바
옌스-피터 볼크메어
Original Assignee
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티, 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 filed Critical 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
Publication of KR20250004896A publication Critical patent/KR20250004896A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020247039741A 2015-12-11 2016-12-08 Cd47 및 egfr의 이중 표적화를 이용한 암의 치료 Pending KR20250004896A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562266470P 2015-12-11 2015-12-11
US62/266,470 2015-12-11
US201662380177P 2016-08-26 2016-08-26
US62/380,177 2016-08-26
PCT/US2016/065641 WO2017100462A2 (en) 2015-12-11 2016-12-08 Treatment of cancer with dual targeting of cd47 and egfr
KR1020187016533A KR102763202B1 (ko) 2015-12-11 2016-12-08 Cd47 및 egfr의 이중 표적화를 이용한 암의 치료

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187016533A Division KR102763202B1 (ko) 2015-12-11 2016-12-08 Cd47 및 egfr의 이중 표적화를 이용한 암의 치료

Publications (1)

Publication Number Publication Date
KR20250004896A true KR20250004896A (ko) 2025-01-08

Family

ID=59013321

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247039741A Pending KR20250004896A (ko) 2015-12-11 2016-12-08 Cd47 및 egfr의 이중 표적화를 이용한 암의 치료
KR1020187016533A Active KR102763202B1 (ko) 2015-12-11 2016-12-08 Cd47 및 egfr의 이중 표적화를 이용한 암의 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187016533A Active KR102763202B1 (ko) 2015-12-11 2016-12-08 Cd47 및 egfr의 이중 표적화를 이용한 암의 치료

Country Status (8)

Country Link
US (3) US10344094B2 (https=)
EP (1) EP3386545A4 (https=)
JP (2) JP7077226B2 (https=)
KR (2) KR20250004896A (https=)
CN (2) CN108367073A (https=)
AU (3) AU2016365829B2 (https=)
CA (1) CA3005911A1 (https=)
WO (1) WO2017100462A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9848673B2 (en) 2015-01-16 2017-12-26 Nike, Inc. Vacuum formed knit sole system for an article of footwear incorporating a knitted component
US10568383B2 (en) 2015-01-16 2020-02-25 Nike, Inc. Sole system for an article of footwear incorporating a knitted component with a one-piece knit outsole and a tensile element
AU2016310348B2 (en) * 2015-08-26 2023-01-05 The Board Of Trustees Of The Leland Stanford Junior University Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
CN108367073A (zh) * 2015-12-11 2018-08-03 小利兰·斯坦福大学托管委员会 以双重靶向cd47和egfr来治疗癌症
PT3402820T (pt) 2016-01-11 2020-08-20 Forty Seven Inc Anticorpos monoclonais anti-cd47 quiméricos, de ratinho ou humanizados
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
EP3532497B1 (en) 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
JP7308191B2 (ja) * 2017-10-18 2023-07-13 フォーティ セブン， インコーポレイテッド 抗ｃｄ４７剤ベースの卵巣癌療法
SG11202004864TA (en) 2017-12-01 2020-06-29 Seattle Genetics Inc Cd47 antibodies and uses thereof for treating cancer
CN111699005A (zh) 2018-02-12 2020-09-22 四十七公司 使用抗cd47抗体和抗cd20抗体的抗癌方案
US20210040219A1 (en) * 2018-03-13 2021-02-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by egfr antibody
PE20201265A1 (es) 2018-03-21 2020-11-19 Alx Oncology Inc Anticuerpos contra proteina alfa reguladora de senal y metodos de uso
CN110331200A (zh) * 2019-06-28 2019-10-15 中山大学附属第六医院 Cd47检测试剂在制备结直肠癌对抗egfr单抗耐药诊断剂方面的应用
WO2021046216A1 (en) * 2019-09-03 2021-03-11 Arch Oncology, Inc. Methods for identifying biomarkers to predict treatment response
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
WO2023165618A1 (en) * 2022-03-04 2023-09-07 Nanjing University Methods for treating cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
EP2111869A1 (en) * 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
HUE032774T2 (en) 2010-04-21 2017-10-30 Ventirx Pharmaceuticals Inc Increase antibody-dependent cellular cytotoxicity
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
EA201390575A1 (ru) * 2010-10-29 2014-01-30 Иммьюноджен, Инк. Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
CA2856411A1 (en) * 2011-11-21 2013-05-30 Immunogen, Inc. Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
ES2816647T3 (es) 2012-01-17 2021-04-05 Univ Leland Stanford Junior Reactivos SIRP-alfa de alta afinidad
US20140134158A1 (en) 2012-05-22 2014-05-15 Alberto Bardelli Kras mutations and resistance to anti-egfr treatment
DK3725807T3 (da) 2012-12-03 2026-01-12 Novimmune Sa Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf
NZ710695A (en) * 2013-02-06 2020-05-29 Inhibrx Inc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
JP2016514676A (ja) * 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 四価二重特異性抗体
CN112245586A (zh) * 2013-03-15 2021-01-22 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
JP6843611B2 (ja) * 2013-04-29 2021-03-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 免疫を強化する抗ｃｄ４７因子の使用
CN106456748A (zh) * 2014-01-08 2017-02-22 小利兰·斯坦福大学托管委员会 小细胞肺癌的靶向疗法
CN106456749B (zh) * 2014-03-11 2021-03-30 小利兰·斯坦福大学托管委员会 抗SIRPα抗体和双特异性巨噬细胞增强型抗体
CA2959821C (en) * 2014-10-24 2024-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA
US20160036232A1 (en) 2015-10-09 2016-02-04 LT Lighting (Taiwan) Corp. Maximum energy utilization point tracking technologies
CN108367073A (zh) * 2015-12-11 2018-08-03 小利兰·斯坦福大学托管委员会 以双重靶向cd47和egfr来治疗癌症
CN107459579B (zh) * 2016-06-01 2021-09-24 泰州迈博太科药业有限公司 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用
CN106519036B (zh) * 2016-11-04 2019-06-11 新乡医学院 抗cd47和egfr的双功能蛋白及其制备方法与应用

Also Published As

Publication number Publication date
AU2023201938B2 (en) 2025-11-20
JP2019505485A (ja) 2019-02-28
AU2020202712A1 (en) 2020-05-14
CN115569192A (zh) 2023-01-06
AU2016365829B2 (en) 2020-02-06
US11130813B2 (en) 2021-09-28
EP3386545A4 (en) 2019-06-05
US20190322751A1 (en) 2019-10-24
JP7077226B2 (ja) 2022-05-30
US20220033506A1 (en) 2022-02-03
US10344094B2 (en) 2019-07-09
CA3005911A1 (en) 2017-06-15
US20170166645A1 (en) 2017-06-15
JP7494245B2 (ja) 2024-06-03
AU2020202712B2 (en) 2023-01-05
AU2023201938A1 (en) 2023-05-04
CN108367073A (zh) 2018-08-03
US12037402B2 (en) 2024-07-16
JP2022116095A (ja) 2022-08-09
EP3386545A2 (en) 2018-10-17
AU2016365829A1 (en) 2018-06-07
WO2017100462A2 (en) 2017-06-15
KR102763202B1 (ko) 2025-02-07
KR20180083895A (ko) 2018-07-23

Similar Documents

Publication Publication Date Title
JP7494245B2 (ja) Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療
JP7343528B2 (ja) 抗ｃｄ４７抗体及び抗ｃｄ２０抗体を使用する抗がんレジメン
KR102418979B1 (ko) Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
KR102776457B1 (ko) 항-cd47 작용제-기초된 난소암 요법
JP7026047B2 (ja) 免疫調節剤を併用するがんの治療
KR102644408B1 (ko) 암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용
JP2023083424A (ja) 血液悪性腫瘍に対するｃｄ４７標的化治療のための投与パラメータ
KR20220091576A (ko) 혈액암의 항-cd47 및 항-cd20 기반 치료
JP2022532519A (ja) 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法
JP2013528599A (ja) 増強デスレセプター・アゴニスト
US20240425604A1 (en) Treatment of immune checkpoint inhibitor-treated cancers with high egfr expression using an antibody that binds at least egfr
JP2025517656A (ja) 腫瘍抗原に特異的である抗体と、ｃｄ４７阻害剤との組合せ
HK40084229A (en) Treatment of cancer with dual targeting of cd47 and egfr
HK1259512A1 (en) Treatment of cancer with dual targeting of cd47 and egfr
JP2023549581A (ja) ツカチニブ及び抗ｐｄ－１／抗ｐｄ－ｌ１抗体の組み合わせによりがんを治療する方法
EA045764B1 (ru) Иммунотерапия злокачественных опухолей путем нарушения передачи сигналов pd-1/pd-l1

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D16-exm-PA0302

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701